Tuesday, April 27, 2010

New report out for biosimilars in use

Dr. David Goldsmith of Guy's Hospital in the UK reports of the new report out looking at some of the first biosimilar technology to have ever been successfully implemented and credited for treating patients.

This article charts a brief history of their use in clinical medicine, mainly dealing with chronic kidney disease, paying special attention to how these agents were introduced into clinical medicine and what has happened subsequently; in 2009, there were several developments that could be regarded as a "perfect storm" in terms of the long-term use of these compounds in chronic kidney disease and oncology and, likely, elsewhere. We are now very much at a "crossroads," where mature reflection is required, because with the latest trials and meta-analyses, these therapies seem not only expensive but also very much a clinical tradeoff (increased risk of adverse effects versus a small gain in fatigue scores).

Read the full article here.

Share this article with your social network, just click below to share now!

No comments :

Post a Comment